Page 35 - Michael Erman News Today

(Reuters) - Some of the world's biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, according to six industry sources. | 06:17am

The European Union should put mechanisms in place to allow drugmakers to charge higher prices in wealthy European countries and lower prices in poorer nations to assure more equitable patient access... | May 5, 2023

The World Health Organization on Friday declared that COVID-19 was no longer a global health emergency, and the virus that led to more than 6.9 million deaths, disrupted the global economy and ravaged... | May 5, 2023

(Reuters) - The World Health Organization on Friday declared that COVID-19 was no longer a global health emergency, and the virus that led to more tha...

By Michael Erman and Maggie Fick BOSTON/LONDON (Reuters) - The European Union should put mechanisms in place to allow drugmakers to charge higher ...

By Michael Erman and Maggie Fick BOSTON/LONDON (Reuters) - The European Union should put mechanisms in place to allow drugmakers to charge higher pric...

NEW YORK, May 4 (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk's Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade... | 12:42pm

NEW YORK (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk's Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. More than half a dozen companies, from Pfizer Inc and Amgen Inc to smaller players like Altimmune Inc, are working on weight-loss therapies similar to Wegovy, viewing them as important future growth drivers. Nov...

Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down in November and will be replaced by current Chief Commercialization Officer Chris Boerner, as the drugmaker contends with increasing generic competition for its top-selling drugs.

(Reuters) - Drugmaker Bristol Myers Squibb on Thursday said its first-quarter sales fell from last year, hurt by generic competition for its cancer drug Revlimid. | 07:07am